Your browser is no longer supported. Please, upgrade your browser.
Settings
NVS Novartis AG daily Stock Chart
NVS [NYSE]
Novartis AG
Index- P/E26.42 EPS (ttm)2.88 Insider Own9.30% Shs Outstand2.69B Perf Week-0.67%
Market Cap203.99B Forward P/E14.87 EPS next Y5.11 Insider Trans0.27% Shs Float2.58B Perf Month4.87%
Income7.02B PEG4.72 EPS next Q1.19 Inst Own9.80% Short Float0.20% Perf Quarter1.23%
Sales50.36B P/S4.05 EPS this Y-33.30% Inst Trans-0.01% Short Ratio2.17 Perf Half Y-13.31%
Book/sh32.30 P/B2.35 EPS next Y7.76% ROA13.30% Target Price93.25 Perf Year-22.47%
Cash/sh1.97 P/C38.47 EPS next 5Y5.60% ROE23.00% 52W Range68.87 - 102.83 Perf YTD-8.26%
Dividend2.72 P/FCF145.40 EPS past 5Y-7.50% ROI7.80% 52W High-26.12% Beta0.58
Dividend %3.58% Quick Ratio0.70 Sales past 5Y-0.50% Gross Margin66.00% 52W Low10.31% ATR0.97
Employees118700 Current Ratio1.00 Sales Q/Q-4.10% Oper. Margin17.80% RSI (14)54.87 Volatility1.01% 1.15%
OptionableYes Debt/Eq0.28 EPS Q/Q-56.40% Profit Margin35.30% Rel Volume0.95 Prev Close76.81
ShortableYes LT Debt/Eq0.21 EarningsApr 21 BMO Payout37.00% Avg Volume2.40M Price75.97
Recom2.40 SMA200.67% SMA502.97% SMA200-9.25% Volume2,267,494 Change-1.09%
Apr-12-16Downgrade Morgan Stanley Equal-Weight → Underweight
Mar-23-16Downgrade Leerink Partners Outperform → Mkt Perform
Jun-22-15Upgrade Bryan Garnier Neutral → Buy
Nov-16-09Initiated Deutsche Securities Buy
Nov-12-09Initiated Barclays Capital Underweight $48
Sep-30-09Upgrade Citigroup Hold → Buy
Sep-15-09Upgrade Jefferies & Co Hold → Buy
Jul-17-09Upgrade JP Morgan Neutral → Overweight
Mar-17-09Initiated Credit Suisse Neutral
Feb-27-09Reiterated Credit Suisse Neutral $14 → $7
Jan-26-09Initiated Jefferies & Co Hold
Sep-23-08Upgrade Credit Suisse Underperform → Neutral
Aug-06-08Downgrade JP Morgan Overweight → Neutral
Jun-12-08Downgrade HSBC Securities Neutral → Underweight $52 → $49
Jun-04-08Upgrade Cowen & Co Neutral → Outperform
May-09-08Upgrade Bernstein Mkt Perform → Outperform
Apr-08-08Downgrade Bear Stearns Outperform → Peer Perform
Feb-29-08Initiated Cowen & Co Neutral
Feb-29-08Downgrade HSBC Securities Neutral → Underweight
Sep-06-07Initiated UBS Buy
Apr-28-16 01:36PM  ETFs with exposure to Novartis AG : April 28, 2016 at Capital Cube
10:06AM  Tysabri Reports Strong Patient Growth in 1Q16 Market Realist
Apr-27-16 11:06AM  Analysts Recommendations: Most Rate Novartis a Buy Market Realist
10:13AM  [$$] Sir Andrew Witty fuels GSK turnround hopes with results boost at Financial Times
10:05AM  Novartis AG :NVS-US: Earnings Analysis: Q1, 2016 By the Numbers at Capital Cube
07:05AM  Glaxo Profit Rises for First Time Since 2013, Tops Estimates at Bloomberg
05:05AM  Novartiss Pharmaceutical Revenue Reported Growth in 1Q16 Market Realist
Apr-26-16 07:09PM  Why Did Sandoz Report Operational Growth? Market Realist
Apr-25-16 11:34AM  Novartiss 1Q16 Earnings Got a Neutral Response from Investors Market Realist
11:34AM  Novartis Reported Operational Growth in Its 1Q16 Earnings Market Realist
09:02AM  Novartis may dispose $13.8B in Roche stake CNBC
05:50AM  April 25 Premarket Briefing: 10 Things You Should Know at TheStreet
12:06AM  [$$] Big Pharma Gets Solace From Europe at The Wall Street Journal
Apr-24-16 09:55AM  Novartis to prepare the sale of its Roche stake: Sonntagszeitung Reuters
Apr-22-16 06:49PM  Does Biotechs Recent Bounce Have Legs? Gurufocus
06:00PM  Biogen Inc Earnings Explode Higher, Revenue Not So Much at Motley Fool
10:20AM  Novartis (NVS) Q1 Earnings Miss; Gleevec Hit by Generics Zacks
08:52AM  Is U.S. Drug Pricing Debate Leaving Europe Feeling Good? at The Wall Street Journal
12:30AM  [$$] Novartis Earnings Fall on Slide in Cancer-Drug Sales at The Wall Street Journal
Apr-21-16 10:41AM  Novartis CEO says "legacy" bribery allegations provisioned for Reuters
10:10AM  Cambridge puts an A (for art) into STEM education, generates some STEAM at American City Business Journals
09:23AM  Europe Warms to New Novartis Heart Drug Amid Glacial U.S. Sales at Bloomberg
09:20AM  [$$] Novartis chief warns of paradigm shift to slower US drug sales at Financial Times
08:25AM  4 Top Jefferies Dividend-Paying Value Stocks to Buy Now at 24/7 Wall St.
08:20AM  Fighting Cancer With Killer T-Cells: 5 Developments To Watch at Forbes
07:59AM  [$$] Novartis Earnings Fall on Slide in Cancer-Drug Sales at The Wall Street Journal
05:33AM  Novartis profits hurt from generic drug competition CNBC
04:42AM  Novartis profits dip as generic rival challenges cancer drug AP
04:36AM  New heart drugs struggle to win sales as doctors hold back Reuters
02:41AM  Novartis (NVS) Misses On Earnings & Sales in Q1 Zacks
01:08AM  Novartis Profit Falls as Blockbuster Cancer Drug Sales Drop at Bloomberg
Apr-19-16 10:00AM  How Will Drug Stocks BIIB, ABT, NVS Perform in Q1 Earnings?
05:50AM  Roche sales set hard challenge for drug industry rivals
Apr-18-16 11:47AM  Will Weak Alcon Sales Hurt Novartis' (NVS) Q1 Earnings?
09:36AM  [$$] Clouds gather over Novartis as it battles series of setbacks at Financial Times
Apr-13-16 09:07AM  IBB Large-Caps: Mylan Launches Generic Version of Lopressor
Apr-12-16 09:38AM  Novartis AG downgraded by Morgan Stanley
Apr-11-16 03:30PM  Novartis Binocrit's Subcutaneous Formula Gets EC Approval
01:59PM  $35M deal: Incyte licenses Lilly drug for potential new use at bizjournals.com
01:06PM  Why Kite Pharma, Inc. Stock Dwindled 10% in March at Motley Fool
Apr-10-16 07:40AM  Could This Biotech Company Be About to Soar Higher? at Motley Fool
02:24AM  VTIAX: Vanguard International Stock Fund's Top 5 Holdings Analysis at Investopedia
Apr-09-16 12:06AM  What Are Incytes Revenue Streams?
Apr-07-16 10:40AM  Novartis' Revolade Approved for Pediatric Patients in the EU
10:30AM  Incyte Buys Rights to Jakafi for Graft-Versus-Host Disease
Apr-06-16 06:16PM  This Deal Sent Incyte Shares Soaring 12% Today at Motley Fool
04:04PM  What Are Novartiss Valuation Multiples?
10:50AM  Pfizer's (PFE) Biosimilar of Remicade Receives FDA Approval
Apr-05-16 07:28AM  Pfizer Vs. Obama: The Treasury Tries To Stop Pharma's Tax Dodge at Forbes
Apr-04-16 05:37PM  Novartis (NVS) Releases Positive Data on Cardiovascular Drug
04:14PM  Fed Worries, Crude Oil Team Up to Beat Down Wall Street at TheStreet
07:05AM  What Do Analysts Expect for Pfizers Profitability?
Apr-03-16 06:55PM  [$$] GSK returns to battle against cancer at Financial Times
Apr-02-16 09:00AM  Novartis takes Entresto case to U.S. cardiologist meeting
Apr-01-16 07:00AM  These Stocks Still Have Room to Run at Morningstar
Mar-31-16 06:06PM  Will Novartiss Alcon Revenues Fall Further in 1Q16?
05:26PM  Opdivo: Bristol-Myers Squibbs Blockbuster Drug
02:35PM  Big Pharma companies that have paid the most in fines at bizjournals.com
02:09PM  Pfizer Tops List of Best Biopharmaceutical Brands at TheStreet
08:48AM  Portola's APEX Trial Design Was Too Clever By Half at Forbes
Mar-30-16 08:04AM  GlaxoSmithKline Reaffirms Its Commitment To Oncology Research But The Strategy Is Unclear at Forbes
Mar-29-16 07:43PM  Novartis probes $US85m bribery allegation AAP
04:21PM  Exclusive: Novartis investigating $85 million bribery allegations in Turkey Reuters
01:55PM  [$$] Sun Pharma to Buy Japanese Brands From Novartis in $293 Million Deal at The Wall Street Journal
12:06PM  How Will Novartiss Sandoz Perform in 1Q16?
11:55AM  Feds' accusation Novartis of 'kickback' scheme could affect Triangle doctors at bizjournals.com
02:06AM  What Does Novartis Expect for Its Pharmaceuticals Segment in 1Q16?
01:07AM  What Do Analysts Estimate for Novartis?
Mar-28-16 03:36PM  Can Novartis Explain 79,236 "Sham" Events? (NVS) at Investopedia
01:01PM  9 Things You Need to Know About Biosimilar Drugs at Motley Fool
07:05AM  How Could Oncology Research Become a Key Driver for Amgen Growth?
Mar-26-16 01:56PM  U.S. Seeks Records of 80,000 Novartis `Sham' Events for Doctors at Bloomberg
Mar-24-16 03:04PM  Will Novartiss 1Q16 Revenues Fall as Expected?
02:59PM  What to Expect from Novartiss 1Q16 Earnings
11:30AM  Eli Lilly's Psoriasis Treatment, Taltz, Gains FDA Approval
Mar-23-16 11:16PM  Drugmaker Novartis settles with US over China bribe claims AFP
08:01PM  Novartis to Settle SEC's China Bribe Case for $25 Million at Bloomberg
05:14PM  Novartis settles civil charges alleging bribery in China - SEC Reuters
04:51PM  Novartis (NVS) Stock Downgraded at Leerink at TheStreet
04:25PM  Novartis settles charges alleging bribery in China - SEC Reuters
02:48PM  5 Popular European Country ETFs in 2016 (EWG, BAYRY) at Investopedia
01:00PM  Novartis Stock Downgraded: 3 Things You Need to Know at Motley Fool
Mar-21-16 04:04PM  GlaxoSmithKline's Search for a New CEO May Revive Underlying Uncertainties at Motley Fool
Mar-20-16 04:04PM  CWGIX: Overview of American Funds Capital World Growth & Income Fund at Investopedia
Mar-18-16 02:54PM  Johnson & Johnsons 1Q16 Earnings: Whats Expected
Mar-17-16 12:08AM  [$$] Novartis Heart-Failure Pill Hits Hurdles With Doctors at The Wall Street Journal
Mar-16-16 03:29PM  [$$] Novartis Heart-Failure Pill Falls Short of Sales Expectations at The Wall Street Journal
10:45AM  Generic Gleevec Will Hurt Novartis -- But Save Millions In Health Costs at Forbes
10:00AM  AVEO Q4 Loss Narrower than Expected, Tivozanib in Focus
12:05AM  What Analysts Are Saying Now about Roche and Peers
Mar-15-16 11:05PM  Is the Growing Vaccine Business a Valuation Catalyst for Sanofi?
11:05PM  Imbruvicas Strong Label Could Boost AbbVies Growth in 2016
10:04PM  Understanding GlaxoSmithKlines Transformation for Growth
10:04PM  Assessing GlaxoSmithKlines Vaccines Business
01:55PM  Valeant Looks Like a Choirboy Next to Mallinckrodt, Says Andrew Left
09:25AM  Jefferies Top Drug Stocks for the Rest of 2016 at 24/7 Wall St.
07:00AM  4 Dividend-Payers From the Ultimate Stock-Pickers at Morningstar
Mar-11-16 09:44AM  The American Dream remains within reach in Switzerland at MarketWatch
Mar-10-16 12:09PM  Two-Armed Cancer Killers Emerging to Rival Custom Cell Therapies at Bloomberg
12:04PM  Bristol-Myers Squibbs Opdivo: Why Is It Important?
Novartis AG researches, develops, manufactures, and markets a range of healthcare products worldwide. It operates through three segments: Pharmaceuticals, Alcon, and Sandoz. The Pharmaceuticals segment offers patented prescription medicines for oncology, neuroscience, retina, immunology and dermatology, respiratory, cardio-metabolic, established medicines, and cell and gene therapies. The Alcon segment provides eye care products, including ophthalmic surgical equipment, instruments, disposable products, and intraocular lenses; medicines to treat chronic and acute diseases of the eye, and over-the-counter medicines for the eye; and contact lenses and lens care products. The Sandoz segment offers generic prescription medicines that include active ingredients and finished dosage forms of pharmaceuticals for dermatology, respiratory and ophthalmic, cardiovascular, metabolism, central nervous system, pain, gastrointestinal, and hormonal therapies; active pharmaceutical ingredients and intermediates primarily antibiotics; protein or other biotechnology-based products; and cytotoxic products for the hospital markets, as well as biotechnology manufacturing services to other companies. The company has collaboration and licensing agreements with Intellia Therapeutics for the discovery and development of new medicines using CRISPR genome editing technology; and with Caribou Biosciences for the development of drug discovery tools. Novartis AG was founded in 1895 and is headquartered in Basel, Switzerland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Novartis Bioventures Ltd10% OwnerApr 12Buy10.00300,0003,000,0002,310,924Apr 12 05:09 PM
Novartis Bioventures Ltd10% OwnerFeb 17Buy8.00375,0003,000,0001,873,791Feb 17 06:47 PM